Heartland Bank & Trust Co Decreases Holdings in Boston Scientific Corporation $BSX

Heartland Bank & Trust Co cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 2.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 9,474 shares of the medical equipment provider’s stock after selling 233 shares during the quarter. Heartland Bank & Trust Co’s holdings in Boston Scientific were worth $1,018,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund raised its stake in Boston Scientific by 0.9% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 127,839 shares of the medical equipment provider’s stock valued at $13,731,000 after buying an additional 1,200 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in Boston Scientific by 6.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 40,748 shares of the medical equipment provider’s stock valued at $4,377,000 after buying an additional 2,293 shares during the last quarter. Welch Group LLC raised its stake in Boston Scientific by 3.5% during the 2nd quarter. Welch Group LLC now owns 4,641 shares of the medical equipment provider’s stock valued at $498,000 after buying an additional 159 shares during the last quarter. Clarendon Private LLC increased its stake in shares of Boston Scientific by 11.5% in the 2nd quarter. Clarendon Private LLC now owns 10,046 shares of the medical equipment provider’s stock worth $1,079,000 after purchasing an additional 1,037 shares in the last quarter. Finally, CWM LLC increased its stake in shares of Boston Scientific by 36.9% in the 2nd quarter. CWM LLC now owns 51,316 shares of the medical equipment provider’s stock worth $5,512,000 after purchasing an additional 13,840 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $18,659,923.46. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $17,972,457 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Needham & Company LLC restated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 1st. Evercore ISI reduced their price objective on Boston Scientific from $115.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Finally, Wells Fargo & Company upped their price objective on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $120.71.

Boston Scientific Trading Down 0.5%

Shares of Boston Scientific stock opened at $94.92 on Tuesday. The company has a market capitalization of $140.64 billion, a P/E ratio of 56.50, a P/E/G ratio of 2.30 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a fifty day moving average of $101.75 and a 200 day moving average of $101.84. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.